287 related articles for article (PubMed ID: 29729523)
1. High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: Implications for cancer stem cell resistance.
Ryoo IG; Choi BH; Ku SK; Kwak MK
Redox Biol; 2018 Jul; 17():246-258. PubMed ID: 29729523
[TBL] [Abstract][Full Text] [Related]
2. Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells.
Ryoo IG; Choi BH; Kwak MK
Oncotarget; 2015 Apr; 6(10):8167-84. PubMed ID: 25717032
[TBL] [Abstract][Full Text] [Related]
3. PA-MSHA inhibits the growth of doxorubicin-resistant MCF-7/ADR human breast cancer cells by downregulating Nrf2/p62.
Wei Y; Liu D; Jin X; Gao P; Wang Q; Zhang J; Zhang N
Cancer Med; 2016 Dec; 5(12):3520-3531. PubMed ID: 27758045
[TBL] [Abstract][Full Text] [Related]
4. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling.
Kim D; Choi BH; Ryoo IG; Kwak MK
Cell Death Dis; 2018 Aug; 9(9):896. PubMed ID: 30166520
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation.
Noman ASM; Parag RR; Rashid MI; Islam S; Rahman MZ; Chowdhury AA; Sultana A; Jerin C; Siddiqua A; Rahman L; Nayeem J; Akther S; Baidya S; Shil RK; Rahman M; Shirin A; Mahmud R; Hossain SMI; Sumi SA; Chowdhury A; Basher SB; Hasan A; Bithy S; Aklima J; Chowdhury N; Hasan MN; Banu T; Chowdhury S; Hossain MM; Yeger H; Farhat WA; Islam SS
Cell Death Dis; 2020 Aug; 11(8):663. PubMed ID: 32814771
[TBL] [Abstract][Full Text] [Related]
6. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
7. Association of CD44
Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
[TBL] [Abstract][Full Text] [Related]
8. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
9. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
Boulbes DR; Chauhan GB; Jin Q; Bartholomeusz C; Esteva FJ
Breast Cancer Res Treat; 2015 Jun; 151(3):501-13. PubMed ID: 25971596
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
12. Association of NRF2 with HIF-2α-induced cancer stem cell phenotypes in chronic hypoxic condition.
Hallis SP; Kim SK; Lee JH; Kwak MK
Redox Biol; 2023 Apr; 60():102632. PubMed ID: 36791645
[TBL] [Abstract][Full Text] [Related]
13. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid hydrogels with defined crosslink density for the efficient enrichment of breast cancer stem cells.
Tan S; Yamashita A; Gao SJ; Kurisawa M
Acta Biomater; 2019 Aug; 94():320-329. PubMed ID: 31125725
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Nrf2 Activity by Chestnut Leaf Extract Increases Chemosensitivity of Breast Cancer Stem Cells to Paclitaxel.
Woo Y; Oh J; Kim JS
Nutrients; 2017 Jul; 9(7):. PubMed ID: 28718813
[TBL] [Abstract][Full Text] [Related]
16. SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma.
Khammanivong A; Gopalakrishnan R; Dickerson EB
Mol Cancer; 2014 Dec; 13():260. PubMed ID: 25471937
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?
Wu T; Harder BG; Wong PK; Lang JE; Zhang DD
Mol Carcinog; 2015 Nov; 54(11):1494-502. PubMed ID: 25154499
[TBL] [Abstract][Full Text] [Related]
18. Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells.
Weitzenfeld P; Meshel T; Ben-Baruch A
Oncotarget; 2016 Dec; 7(49):81123-81143. PubMed ID: 27835603
[TBL] [Abstract][Full Text] [Related]
19. Nrf2/p62 signaling in apoptosis resistance and its role in cadmium-induced carcinogenesis.
Son YO; Pratheeshkumar P; Roy RV; Hitron JA; Wang L; Zhang Z; Shi X
J Biol Chem; 2014 Oct; 289(41):28660-75. PubMed ID: 25157103
[TBL] [Abstract][Full Text] [Related]
20. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
